---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003962"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T03:58:20.668158+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Board director Carol Ashe resigns from Aptose Biosciences, effective immediately

## Summary
- Carol Ashe resigned from the Board of Aptose Biosciences effective June 16, 2025.
- Resignation not due to any disagreement with the company's operations, policies, or practices.
- No replacement director named in the filing.

## SEC filing metadata
- accession: 0001171843-25-003962
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325003962/0001171843-25-003962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325003962/f8k_061825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003962
- JSON: https://secwatch.observer/filing/0001171843-25-003962.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003962.txt

## Key facts
- Executive change
  Carol Ashe resigned as member of the Board at Aptose Biosciences Inc..
  - Action: resigned
  - Role: member of the Board
  source text: On June 16, 2025, Carol Ashe notified the Board of Directors (the “Board”) of Aptose Biosciences Inc. (the “Company”) of her intention to resign from her role as a member of the Board effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184325003962/0001171843-25-003962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.